CLOT Conversations

Oral anticoagulant drug considerations in Cancer: Dr Tzu-Fei Wang

Season 2 Episode 15

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 10:38

Send us Fan Mail

In this episode of Clot Conversations, Dr. Tzu-Fei Wang, Ottawa, shares a summary of her presentations at the 2025 ISTH meeting on recent studies on drug interactions in prostate cancer therapy and the use of anticoagulants. Dr Wang also highlights the significance of the WAVe study in assessing dalteparin use without the traditional dose cap in patients over 90 kg. These findings offer reassurance to clinicians prescribing anticoagulation therapy, minimizing previous concerns. The discussion provides optimism for improved cancer care protocols, showcasing safer, more effective anticoagulation practices for patients..

Support the show

https://thrombosiscanada.ca

Register today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026Conference

Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada